Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
0.5202
-0.2529 (-32.71%)
At close: Sep 21, 2026, 4:00 PM EDT
0.5232
+0.0030 (0.58%)
After-hours: Sep 21, 2026, 7:59 PM EDT
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,913,235
Market Cap
10.13M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - | 17 | 0 |
| Dec 31, 2024 | 17 | -1 | -5.56% | 17 | 0 |
| Dec 31, 2023 | 18 | -1 | -5.26% | 18 | 0 |
| Dec 31, 2022 | 19 | 2 | 11.76% | 15 | 4 |
| Dec 31, 2021 | 17 | 2 | 13.33% | 13 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Enlivex | 34 |
| Cerenome | 28 |
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| Lisata Therapeutics | 21 |
| SeaStar Medical Holding | 18 |
| Intensity Therapeutics | 7 |
| Dyadic International | 5 |
MBRX News
- 7 days ago - Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings - GlobeNewsWire
- 10 days ago - Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - GlobeNewsWire
- 10 days ago - Moleculin Biotech Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 24 days ago - Moleculin Biotech price target lowered to $3 from $22 at H.C. Wainwright - TheFly
- 25 days ago - Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference - GlobeNewsWire
- 4 weeks ago - Moleculin Biotech Proxy statement: Proxy filing - Filings
- 4 weeks ago - Moleculin Biotech Proxy statement: Proxy filing - Filings
- 5 weeks ago - Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial - GlobeNewsWire